Results 71 to 80 of about 2,559,166 (272)

Sustained Delivery of a Shingles Subunit Vaccine Overcomes Age‐Related Declines in Humoral and Cellular Immunity Relative to Shingrix

open access: yesAdvanced Science, EarlyView.
Sustained delivery of a shingles subunit vaccine from an injectable polymer–nanoparticle hydrogel enhanced the potency, durability, and breadth of immune responses in aged mice while minimizing inflammatory cytokine production and reactogenicity. This strategy decouples immunogenicity from reactogenicity and offers a promising approach to improve ...
Ye Eun Song   +5 more
wiley   +1 more source

Cobalt Single‐Atom Nanozyme for Enhanced Intestinal Radioprotection and Tumor Radiosensitization via Bidirectional ROS Modulation

open access: yesAdvanced Science, EarlyView.
Orally administered, pH‐responsive Co‐SAN exerts dual functions: in the alkaline intestinal milieu, it scavenges reactive oxygen species (ROS) and suppresses the PI3K/AKT pathway and NETs formation, thus providing radioprotection; whereas in the acidic tumor microenvironment, it generates ROS and alleviates hypoxia, thereby enhancing radiosensitization.
Shengqi Yin   +13 more
wiley   +1 more source

The exploration of medical resources utilization among inguinal hernia repair in Taiwan diagnosis-related groups

open access: yesBMC Health Services Research, 2017
Background This study centered on differences in medical costs, using the Taiwan diagnosis-related groups (Tw-DRGs) on medical resource utilization in inguinal hernia repair (IHR) in hospitals with different ownership to provide suitable reference ...
Yu-Hua Yan, Chih-Ming Kung, Yi Chen
doaj   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

open access: yesAdvanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou   +11 more
wiley   +1 more source

Modbury Hospital Foyer shot

open access: yes
Black and White photograph of the Modbury Hospital main ...
Modbury Hospital
core   +1 more source

Risk of Inflammatory Bowel Disease Following Hospital‐Treated Infections and Modulatory Role of Host Genetics to Support a Multi‐Hit Pathogenesis Model

open access: yesAdvanced Science, EarlyView.
Hospital‐treated infections are linked to increased risk of inflammatory bowel disease in a large prospective cohort. This risk differs by infection burden, time since infection, and host immune‐genetic susceptibility. The findings support a multi‐hit pathogenesis model in which severe infection and inherited susceptibility jointly shape inflammatory ...
Haiming Zhuang   +16 more
wiley   +1 more source

The hospital administrator.

open access: yesSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1998
No ...
openaire   +2 more sources

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

open access: yesAdvanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv   +14 more
wiley   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

open access: yesAdvanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy